The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 353.60
Bid: 354.80
Ask: 355.40
Change: 0.00 (0.00%)
Spread: 0.60 (0.169%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 353.60
QQ. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Fourth Quarter Trading Update

20 Apr 2022 07:00

RNS Number : 6600I
QinetiQ Group plc
20 April 2022
 

News release

 

QinetiQ Group plc

Fourth Quarter Trading Update

20 April 2022 - QinetiQ Group plc ("QinetiQ" or "the Group") today issues a trading update covering its fourth quarter to 31 March 2022.

Strong operational performance in fourth quarter - ahead of full year guidance

Through continued disciplined execution of our strategy, the Group has delivered strong operational performance through the fourth quarter. Today we are pleased to announce that we expect our results for the full year to 31 March 2022 to be marginally ahead of our previous guidance and current market consensus expectations.

Full year order intake has been very strong at more than £1.2bn and, subject to audit, we expect to deliver c.5% revenue growth on an organic basis with underlying operating profit of at least £135m. Operating cash flow has been excellent and we retain a strong balance sheet with net cash at 31 March 2022 of c.£225m.

Our strong performance has been driven by significant growth in EMEA Services, partially offset by the slower recovery in Global Products. We saw continued excellent growth in Australia and the UK driven by good programme execution and delivery across all our major contracts. US revenue performance recovery was slower than expected, with the second half in line with the first half, largely due to the US defence budget being constrained by the extended Continuing Resolution. However, we secured 20% year-on-year growth in order intake which, coupled with our new leadership team, provides a strong foundation for the delivery of our US growth strategy. The complex project contract is now closed and the financial impact remains the £14.5m write-down fully contained in our first half results.

We retain our medium to long-term guidance: we are targeting mid-single digit percentage compound annual organic revenue growth over the next five years, with strategic acquisitions further enhancing this growth. We are targeting a long-term operating profit margin of 12-13%, although in the short-term we anticipate margins being c.100bps lower, driven by inflationary pressures and continued investment. Capital expenditure for FY23 is expected to be at the upper end of the £90m to £120m per annum range, consistent with our previous guidance.

Steve Wadey, Group Chief Executive Officer said:

"I am extremely proud of how our people have continued to deliver critical defence and security capabilities for our customers, despite the ongoing challenges of the pandemic. Recent world events have reinforced the long-term needs of our customers, including capabilities utilising differentiated technology, test and training solutions which are directly aligned with our strategy. With a clear focus on disciplined execution of our strategy, increasing demand for our solutions and good revenue coverage, we have positive momentum to deliver sustainable growth in the coming years and are maintaining expectations for Group performance."

Investor seminar 27 April 2022

We are hosting an investor seminar on 27 April 2022 at The Smith Centre at The Science Museum, Exhibition Road, South Kensington, London, SW7 2DD. The presentation will cover our global ambition with a particular focus on the US and Australia. You are invited to join us for lunch from 12.30pm BST to see a selection of our products and capabilities, as well as meeting the QinetiQ Leadership Team. The presentation will run 1.30-3.30pm BST and there will be an option to view online if you cannot join us in person. More information including how to register can be found on our website here:

https://www.qinetiq.com/en/investors/investor-seminars/delivering-global-growth

Preliminary results

We will announce our preliminary results on 19 May 2022. We will be hosting an in-person results presentation, details of which will be available on our website shortly at: www.QinetiQ.com/investors.

About QinetiQ

QinetiQ (QQ.L) is a leading science and engineering company operating primarily in the defence and security markets. We work in partnership with our customers to solve real world problems through innovative solutions delivering operational and competitive advantage. Visit our website www.QinetiQ.com. Follow us on LinkedIn and Twitter @QinetiQ. Visit our blog www.QinetiQ-blogs.com.

For further information please contact:

John Haworth, Group Head of Investor Relations:

+44 (0) 7920 545841

Lorna Cobbett, Citigate Dewe Rogerson (Media enquiries):

+44 (0) 7771 344781

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBLGDSSXBDGDC
Date   Source Headline
12th Apr 202212:45 pmRNSDirector/PDMR Shareholding
10th Mar 202211:27 amRNSDirector/PDMR Shareholding
10th Feb 202211:52 amRNSDirector/PDMR Shareholding
10th Feb 202211:52 amRNSDirector/PDMR Shareholding
2nd Feb 20228:42 amRNSHolding(s) in Company
24th Jan 202211:12 amRNSDirector/PDMR Shareholding
19th Jan 20221:43 pmRNSHolding(s) in Company
18th Jan 20227:00 amRNSThird Quarter Trading Update
17th Jan 20227:00 amRNSAppointment of President and CEO of QinetiQ US
11th Jan 202211:43 amRNSDirector/PDMR Shareholding
5th Jan 20225:05 pmRNSDirector/PDMR Shareholding
20th Dec 20219:21 amRNSDirector Declaration
10th Dec 202112:42 pmRNSDirector/PDMR Shareholding
6th Dec 202112:16 pmRNSHolding(s) in Company
18th Nov 202111:04 amRNSDirector/PDMR Shareholding
17th Nov 202110:54 amRNSDirector/PDMR Shareholding
16th Nov 202111:24 amRNSDirector/PDMR Shareholding
11th Nov 20217:00 amRNSInterim Results
10th Nov 202112:12 pmRNSDirector/PDMR Shareholding
1st Nov 202111:43 amRNSBlock listing Interim Review
19th Oct 20219:16 amRNSHolding(s) in Company
14th Oct 20217:00 amRNSTrading Update
12th Oct 202110:43 amRNSDirector/PDMR Shareholding
10th Sep 20212:07 pmRNSDirector/PDMR Shareholding
31st Aug 20212:35 pmRNSDirector/PDMR Shareholding
11th Aug 20219:07 amRNSDirector/PDMR Shareholding
27th Jul 202110:46 amRNSDirectorate Change
26th Jul 20214:33 pmRNSDirector/PDMR Shareholding
21st Jul 202110:55 amRNSResult of AGM
21st Jul 20217:00 amRNSFirst Quarter Trading Update
14th Jul 20218:47 amRNSChange of AGM venue
13th Jul 20219:52 amRNSHolding(s) in Company
12th Jul 202111:12 amRNSDirector/PDMR Shareholding
2nd Jul 20217:00 amRNSChief Financial Officer succession
29th Jun 20213:49 pmRNSDirector/PDMR Shareholding
15th Jun 202110:55 amRNSAnnual Financial Report
10th Jun 202111:15 amRNSDirector/PDMR Shareholding
9th Jun 20215:01 pmRNSDirector/PDMR Shareholding
1st Jun 20219:34 amRNSTotal Voting Rights
25th May 202110:54 amRNSBlock Listing Application
20th May 20217:00 amRNSPreliminary Results
11th May 20211:53 pmRNSDirector/PDMR Shareholding
27th Apr 20212:08 pmRNSDeath of Non-Executive Director, Ian Mason
15th Apr 20212:49 pmRNSHolding(s) in Company
14th Apr 20217:00 amRNSTrading Update
12th Apr 20212:00 pmRNSDirector/PDMR Shareholding
12th Apr 20218:32 amRNSHolding(s) in Company
10th Mar 202112:23 pmRNSDirector/PDMR Shareholding
4th Mar 20217:00 amRNSInvestor Seminar
16th Feb 20218:55 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.